We are a clinical-stage biopharmaceutical company with a proven track record of discovering and developing new medicines that treat patients living with debilitating diseases and conditions. We build on a chemistry platform that was invented in our labs along with our scientific expertise to focus on developing unique and more precise medicines.
Our success is rooted in four key elements:
- Our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners
- Our unique research and development pipeline of new investigational medicines in cancer, pain and immunology
- Our proprietary and proven science approach that fuels our discovery efforts
- Our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We also have a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.
Latest and Upcoming Investor Events
NKTR-181 HAP Study Results Call
Jul 18, 2017 at 8:45 AM ET
Contact Nektar Investor Relations
Vice President of Investor Relations and Corporate Affairs
Director, Investor Relations & Corporate Communications
Transfer Agent and Stockholder Services
Computershare Shareholder Services
P.O. Box 43006
Providence, RI 02940-3006